睿学教育Wisdome Education

Cornelia Liu Trimble, M.D.

• Professor of Gynecology and Obstetrics

https://www.hopkinsmedicine.org/profiles/results/directory/profile/0007730/angelo-demarzo

Trimox dosages: 500 mg, 250 mg
Trimox packs: 30 pills, 60 pills, 90 pills, 120 pills, 180 pills, 270 pills, 360 pills

Buy generic trimox 250 mg line

Charbit B commonly used antibiotics for acne trimox 500 mg buy otc, Albaladejo P virus e68 order discount trimox line, Funck-Brentano C antibiotic invanz cheapest generic trimox uk, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: A prospective comparative study. BJOG: An International Journal of Obstetrics and Gynaecology. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Antiemetics Page 59 of 136 Final Report Update 1 Drug Effectiveness Review Project Appendix A. US Food and Drug Administration recommendations for adult dosages a,b I. Dosages for prevention of emesis associated with chemotherapy Emetic risk Drug (brand name) Form Moderate High Aprepitant (Emend ) Capsule 125 mg once on day 1 then 125 mg once on day 1 80 mg once daily on days 2 then 80 mg once daily to 3 on days 2 to 3 Fosaprepitant Injection 115 mg IV once on day 1 115 mg IV once on day (Emend ) then 80 mg orally once 1 then 80 mg orally daily on days 2 to 3 once daily on days 2 to 3 5-HT3 antagonists Dolasetron (Anzemet ) Injection 1. Dosages for prevention of postoperative emesis a Drug (brand name) Form Dosage Aprepitant (Emend ) Capsule 40 mg once Fosaprepitant (Emend ) Injection Not established 5-HT3 antagonists Dolasetron (Anzamet ) Injection 12. Antiemetics Page 60 of 136 Final Report Update 1 Drug Effectiveness Review Project III. Dosages for prevention of emesis following radiotherapy a Drug (brand name) Form Dosage Granisetron (Kytril ) Injection Not established Tablet, oral solution 2 mg once Ondansetron (Zofran ) Injection Not established Tablet, orally 8 mg three times daily disintegrating tablet, oral solution a Administered prior to radiotherapy, unless otherwise specified. Antiemetics Page 61 of 136 Final Report Update 1 Drug Effectiveness Review Project Appendix B. US Food and Drug Administration recommendations for pediatric dosages I. Prevention of emesis following chemotherapy with moderate to high emetic risk b Drug (brand name) Form Age range Dosage Aprepitant/fosaprepitant Injection/Capsule N/A Not established (Emend ) a Dolasetron (Anzemet ) Injection, Tablet 2 to 16 1. Prevention of postoperative emesis a Drug (Brand Name) Form Age range Dosage Aprepitant/fosaprepitant Injection/Capsule N/A Not established (Emend ) Dolasetron (Anzemet ) Injection (prevention or 2 to 16 0. Antiemetics Page 62 of 136 Final Report Update 1 Drug Effectiveness Review Project Appendix C. Glossary This glossary defines terms as they are used in reports produced by the Drug Effectiveness Review Project. Some definitions may vary slightly from other published definitions. Absolute risk: The probability or chance that a person will have a medical event. It is the ratio of the number of people who have a medical event divided by all of the people who could have the event because of their medical condition. Add-on therapy: An additional treatment used in conjunction with the primary or initial treatment. Adherence: Following the course of treatment proscribed by a study protocol. Adverse drug reaction: An adverse effect specifically associated with a drug. Adverse event: A harmful or undesirable outcome that occurs during or after the use of a drug or intervention but is not necessarily caused by it. Adverse effect: An adverse event for which the causal relation between the intervention and the event is at least a reasonable possibility. Active-control trial: A trial comparing a drug in a particular class or group with a drug outside of that class or group. Allocation concealment: The process by which the person determining randomization is blinded to a study participant’s group allocation. Applicability: see External Validity Before-after study: A type nonrandomized study where data are collected before and after patients receive an intervention. Before-after studies can have a single arm or can include a control group. Bias: A systematic error or deviation in results or inferences from the truth. Several types of bias can appear in published trials, including selection bias, performance bias, detection bias, and reporting bias.

Discount trimox online visa

Dashesshow cases in which the recep- torsiteisnot properly expressed medication for uti bladder spasm trimox 250 mg buy on line. Redrawn from Skehel and Wiley (2000) antibiotic resistance headlines buy generic trimox line, with permission from the Annual Review of Biochemistry infection control in hospitals trimox 250 mg purchase without prescription, www. The sialic acid has been displaced slightly to show the structure of the fit. The amino acids numbered within and around the binding site provide a reference for the location of important residues. The bottom of the figure shows the effect on binding affinity to sialic acid caused by experimental change of particular amino acids. This space-filling model has roughly the same orientation as the schematic diagram in figure 13. Antibodies bound to HA can neutralizeinfluenza infectivity by physi- cally obstructing the sialic acid binding site. For example, the HC19 MAb binds to HA of strain X-31 (H3 subtype),partially overlapping the sialic acid binding site (Bizebard et al. The specific antibody-epitope re- gion of direct contact covers 1250 Å2,including amino acids 134, 136, 212 CHAPTER 13 153, 155, and 194. The de- pression extends 315 Å2,ofwhichtheantibody binding region covers 167 Å2. Antibody escape mutants map to the ridge of amino acids that ring the conserved amino acids in the binding pocket. Each upper arm forms an Fab frag- ment, with the binding region on the tip of the fragment. An antibody molecule can be cleaved to release two identical Fab fragments, each containing a binding region. However, other antibody escape mutants map to regions of HA away from the sialic acid binding site. Those sites are too far away to allow overlap of the direct antibody- epitope binding region with the sialic acid binding site. The Fab fragment of HC45 bound to its epitope with approximately the same kinetics as HC19 bound to its epitope, but HC19 was an order of mag- nitude more efficient at neutralization. Presumably this occurs because the Fab of HC19 causes greater obstruction of binding to sialic acid than does the more distantly bound Fab of HC45. By contrast, the full anti- body molecules of HC19 and HC45 neutralized virus in proportion to their binding affinity for their respective epitopes. HC19 binds to the tips of HA molecules away from the viral surface; thus HC19 faces relatively little obstruction when binding to intact HA on viruses. By contrast, HC45 binds away from the tips of HA, towardtheviralsurface. This requires HC45 to diffuse through the HA spikes, slowing the rate of HA-HC45 association and reducing the net affinity of the binding. Clearly, neu- tralization depends on the structural environment of intact epitopes. EXPERIMENTAL EVOLUTION: INFLUENZA 213 Other studies have noted differencesbetween antibodies in their re- lationsbetween binding and neutralization (Dimmock 1993; Schofield et al. The siteofantibody attachment, the kinetics of antibody binding, and the mechanism by which antibodies interfere with viral success all likely play a role in determining the strength of natural selection onvarious re- gions of the HA molecule. Bulky side chains may cause steric hindrance that interferes with antibody-epitope contact. Glycosy- lation adds surface carbohydrates that can prevent antibody access to potential epitopes (Caton et al. Alterna- tively, amino acid changes sometimes cause physical displacement of various protein loops. When the antibody bound to the mutantepitope, the antibody-epitope complex reverted to the same structure as the antibody bound to the original type.

Diseases

• Kozlowski Brown Hardwick syndrome
• Retinohepatoendocrinologic syndrome
• Primary alveolar hypoventilation
• Mousa Al din Al Nassar syndrome
• Amelia cleft lip palate hydrocephalus iris coloboma
• Melanoma-astrocytoma syndrome
• Spastic dysphonia
• Phocomelia contractures absent thumb
• Acute myeloblastic leukemia type 3

Trimox 250 mg order overnight delivery

Steps that affect fitness relatively weakly will accumulate relatively more variation virus 7 life processes 250 mg trimox sale, un- til a balance of mutation and selection occurs antibiotics libido discount 500 mg trimox visa. Steps that affect fitness strongly will accumulate relatively less variation antibiotic tooth infection generic trimox 500 mg buy on line. In each case, the vari- ation in fitness will be roughly the same. The major polymorphisms likely arise by processes in addition to mutation-selection balance. In those cases, various trade-offs between immune control of parasites and collateral damage probably balance the fitnesses of different variants. The collateral damage may be inflam- matory or other negative effects of a hyperimmune response, as in the gastric tissue damage promoted by IL6. Or more rarely, the damage may arise from reducing the proliferation of immune cells that normally con- trol pathogens but also can be the target of parasitic attack. This latter trade-off appears to occur in IL10 control of macrophages in the context of HIV-1 infection. Regulatory variability may sometimes alter immunodominance be- cause cytokines modulate positive and negative stimulation of T and Bcell clones. In their study, normal levels of interferon-γ were associated with about a 5-fold ratio of immunodominant to subdominant T cell clones for two Listeria monocytogenes epitopes. By contrast, reduced interferon-γ was associated with roughly equivalent clonal expansion of CTLs specific for these two epitopes. Im- munodominance, in turn, affects the intensity of selection on particular GENETIC VARIABILITY OF HOSTS 121 pathogen epitopes. Thus, variations in immune regulation may influ- ence patterns of antigenic variation. Parasites may fa- vor change in the frequencies of host MHC alleles. For example, the human class I MHC molecule B35 binds to common epitopes of Plasmo- dium falciparum’s circumsporozoite protein (Gilbert et al. The B35 allele occurs in higher frequency in The Gambia, a region with en- demic malaria, than in parts of the world with less severe mortality from malaria. It would be interesting to know if variant epitopes influence the fre- quency of matching MHC alleles. For example, one epitope variant may be common in one location and another variant common in another lo- cation. Do those variants affect the local frequencies of MHC alleles in the host population? This questionfocuses attention on the kind of selection pressure parasites impose on MHC alleles. Each MHC allele may have a qualitative relationship with each par- ticular epitope, in that one amino acid substitution in the epitope can have a large effect on binding. But over the lifetime of an individual, each MHC type meets many potential epitopes from diverse parasites. Thus, MHC alleles vary quantitatively in the net benefit they provide by their different matches to the aggregate of potential epitopes. It may be rather rare for a single parasite to impose strong, sustained pressure on a particular MHC allele. Perhaps only major killers of young hosts can cause such strong selection. Mathematical models could clarify the nature of aggregate selection imposed on MHC alleles. Does the distri- bution of MHC alleles in the host population shape the distribution of antigenic variants? It would be interesting to compare parasites in two locations, each location with hosts that have different frequencies of MHC alleles. In principle, differing host MHC profiles could influence antigenic varia- tion. Each epitope could potentially interact with several MHC alleles. The net effect depends on the balance of fitness gains by an escapesubstitution against one MHC allele and the potential costs of that substitution in terms of functional 122 CHAPTER 8 performance and the possibility of creating enhanced binding to other MHC alleles.

Trimox 500 mg buy free shipping

Candesartan compared with perindopril and trandolapril Candesartan was compared with perindopril and trandolapril in a single randomized controlled 91 trial bacteria 6 kingdoms purchase trimox discount, and will be discussed together infection urinaire femme buy trimox 250 mg online. This study also compared losartan to perindopril and trandolapril and is described above antibiotics for uti cefuroxime buy trimox 500 mg with visa. Comparison doses were candesartan 4 mg per day, perindopril 2 mg per day, and trandolapril 0. All treatment groups showed significant decline in proteinuria compared with baseline at 1 and 96 weeks. Only the 12-week percent decline was reported for candesartan (38%), but that anti-proteinuric effect was reported as being “sustained” throughout the duration of the study. The perindopril group experienced – 43% and –61% declines in proteinuria at 12 and 96 weeks respectively and the trandolapril group experienced –38% and –54% declines in proteinuria at 12 and 96 weeks respectively. No inter- group statistical comparisons are reported between these therapies. Blood pressure control was reported to statistically the same between groups, and no statistically significant change in creatinine clearance was noted during the study. Withdrawals and adverse events were not reported for this trial. Valsartan Valsartan compared with lisinopril Valsartan was compared with lisinopril in 1 multi-center randomized double-crossover study 83 across 5 states in the United States. This study included 37 participants, all of whom had chronic kidney disease, although the types of chronic kidney diseases among participants were not reported. Participants were randomized to valsartan 80 mg daily or lisinopril 10 mg daily, and were crossed over into each treatment arm after an DRIs, AIIRAs, and ACE-Is Page 54 of 144 Final Report Drug Effectiveness Review Project intervening washout period. This study was rated as fair due to small sample size and lack of adverse event reporting. Doses of comparison medications included lisinopril 10 mg per day and valsartan 80 mg per day. The primary and secondary endpoints of this trial were not concordant with topics of interest for our review (change in serum potassium with an AIIRA compared with an ACE-I, serum aldosterone and renin levels on an AIIRA compared with an ACE-I), but this study did examine changes in glomerular filtration rates on these therapies. Calculations based on provided glomerular filtration rate values showed a rough 4% increase in glomerular filtration rate for those treated with losartan compared with a 3% decline in glomerular filtration rate for those treated with valsartan. No significant change in glomerular filtration rate compared with baseline was noted in either arm after completion of therapy, and no statistical analysis between groups was reported. Blood pressure decline was noted to be similar in each group, although statistical analysis on blood pressure decline was not reported. A subgroup analysis was done by dividing participants into those with estimated glomerular filtration rate of greater compared with less 2 than 60 ml/min/1. Two participants were withdrawn from this study, but reason for withdrawal was not reported. The number of hyperkalemic events was not reported, but authors did note a statistically significant difference in potassium levels between treatment arms. Valsartan compared with benazepril 84 Valsartan was compared with benazepril in 2 studies (N=60), which took place in Italy and 105 Spain. Both studies compared escalating doses of valsartan (80 mg then increased to 160 mg daily) and benazepril (10 mg then increased to 20 mg daily), although 1 study limited benazepril 20 mg daily to those with creatinine clearance greater 105 than 50 ml/min. These 2 trials were heterogeneous in terms of participant characteristics and 105 types of chronic kidney disease. Follow-up was 6 months in 1 trial and 32 weeks in the 84 other. One trial enrolled participants with chronic glomerulonephritis, IgA nephropathy, and 84 “other” types of renal disease (biopsy was not required), while the other did not report types of chronic kidney disease in their participants. Both studies required participants to be proteinuric; 84 baseline proteinuria levels were 3 grams per day in 1 trial and ranged from 3. Both trials also included participants with similar baseline creatinine clearance values (69-74 ml/min on average). Doses of compared medications did differ between 84 these trials; 1 trial used benazepril 10 mg per day and valsartan 80 mg per day, and the other used either benazepril 10 or 20 mg per day (depending on level of creatinine clearance) and 105 valsartan starting at 80 mg per day but then increased to 160 mg per day. Two studies reported overall changes in proteinuria from baseline. One study reported percent reduction in proteinuria compared with baseline, and values appeared numerically similar between groups (–41% and –45% for valsartan and benazepril 84 respectively). No statistically significant difference in proteinuria reduction was noted between valsartan and benazepril therapy.

Discount trimox 500 mg without a prescription

Therapies that target key cellular pathways/attributes specific for Because the cognate antigen for a particular BCR is usually not tumor cells are envisioned as a better way to treat cancer oral antibiotics for sinus infection trimox 500 mg buy without a prescription. In certain known antibiotic chicken order trimox 250 mg, this binding is often experimentally modeled with an diseases antibiotic tendon rupture generic 250 mg trimox mastercard, such as chronic myelogenous leukemia, targeted therapies antibody reagent derived from immunoglobulin generated in a have substantiated this vision. It has long been suspected that the nonhuman species and directed against constant regions of human B-cell receptor (BCR), the defining attribute of normal and neoplas- IgH or IgL. BCR “cross-linking” with this reagent mimics the tic B cells, would be an effective target in BCR-expressing malignan- binding of polyvalent antigen and initiates a rapid cascade of cies. Recent years have seen a convergence of new preclinical evidence well-known proximal phosphorylation events, involving multiple that BCR signaling is critical to most B-cell malignancies, the kinases and adaptor molecules including Src family kinases (SFK, development of clinic-ready targeted agents inhibiting BCR-activated chiefly LYN), spleen tyrosine kinase (SYK), Bruton tyrosine kinase signaling pathways, and clinical trials demonstrating the striking (BTK), and PI3K. Active BCR signaling is therefore “druggable” effectiveness of these agents. Despite the success of BCR-targeting 1 by small-molecule inhibitors (SMIs) of several kinases, potentially therapy for B-cell malignancies, summarized in a recent review article, preventing the activation of one or more of the distal signaling questions remain about how best to translate BCR-targeting therapy to pathways that drive proliferation, growth, and survival: NF- B, the clinical setting. This review discusses briefly the molecular biology NFAT, MAPK, and AKT/mTOR. Most evidence Molecular biology of BCR signaling in B-cell supporting this implication comes from chronic lymphocytic leuke- malignancies mia/small lymphocytic lymphoma (CLL/SLL), which can be di- A B cell is defined and created by the productive rearrangement of vided into 2 types of cases. In unmutated (U) cases, the variable (V), immunoglobulin heavy (IgH) and light (IgL) chain genes, leading to diversity (D), and joining (J) segments of the IgH and IgL genes that Hematology 2013 553 have been selected by recombination to encode HVRs have ABC-DLBCL cell lines. Sequencing found that most of these lines, germline sequences. In mutated (M) cases, these segments have and 24% of primary ABC-DLBCL tumors, had mutations in the undergone somatic hypermutation, the normal process in germinal immunoreceptor tyrosine activation motif (ITAM) domains of centers by which the affinity of BCR for its cognate antigen is CD79A and CD79B genes, which normally serve as substrates for increased. Both U and M cases display “stereotyped” nonrandom phosphorylation by SFK and activation of SYK via its tandem SH2 utilization of V, D, and J segments, and HVRs from some M cases domains. The molecular consequences of these ITAM mutations is have identical nucleotide sequences, both of which imply selection not entirely clear, although they appear to enhance BCR signaling for binding to a common self-antigen. Although the BCR of CLL by promoting surface BCR expression and reducing signal- cells has often been considered to resemble “natural” polyreactive terminating LYN kinase activity. Nonetheless, the frequency of antibodies characteristic of normal marginal zone B cells, specific these BCR-activating mutations in primary tumors is strong evi- antigens recognized by CLL/SLL cells have been identified, mostly dence for “chronic active” BCR signaling in ABC-DLBCL. Of of self-origin2,3 but also of fungal origin in some cases. After productive have nonstereotyped BCRs that bind to a common autoantigen in IgH rearrangement, early B-cell precursors in the BM express a the N-terminal region of vimentin. In the periphery, mature B cells continue to depend on tonic by the HVR: unusually frequent mutations in IgH scaffold regions BCR signaling, as shown by their disappearance upon conditional lead to abnormal sites of N-glycosylation in FL IgH chains,9 which 19 deletion of IgH or CD79A. In contrast, conditional deletion of may be bound by microenvironmental lectins and trigger BCR members of the CARD11/ BCL10/MALT1 complex, essential for signaling. Frequent (70%) mutations in TCF3 or its malignancies has additional implications. One is that self-reactivity negative regulator ID3 in BL cell lines and primary tumors were by B-cell malignancies implies a defect in tolerance mechanisms found to be associated with increased expression of IgH and IgL, that normally prevent development of self-reactive B cells. Al- and RNA interference studies showed dependence on CD79A and SYK but not CARD11. This was found to be the case for the activated B-cell (ABC) tions. In acute and chronic active BCR signaling, BTK is subtype of diffuse large B-cell lymphoma (DLBCL), originally phosphorylated by SYK and then phosphorylates phospholipase defined by having a gene expression profile with similarities to that C 2, leading to activation of protein kinase C beta and, in turn, of normal memory B cells activated by acute BCR cross-linking,14 CARD11. Ibrutinib (PCI-32765) is an orally available, selective and subsequently found to depend on NF- B activation by the kinase inhibitor that irreversibly binds to the Cys-481 residue of CARD11/ BCL10/MALT1 complex. Early preclinical studies demonstrated ibrutinib’s ability to found that the viability of most ABC-DLBCL cell lines was block BCR signaling in normal peripheral B cells and induce compromised by knock-down of several signaling proteins down- response in animals with lymphoma. No cumulative hematologic with 2 IgH and 2 IgL disulfide bond-linked chains to comprise the or nonhematologic toxicity was reported in patients with pro- BCR, were also found to be required for viability of BCR-dependent longed dosing. There was no significant reduction in normal 554 American Society of Hematology Figure 1.

Syndromes

• Throat swelling (which may also cause breathing difficulty)
• Increased risk of hardening of the arteries
• Other medicines, such as antibiotics
• Eggs
• Oxygen
• Are tall and thin
• Heartburn
• Larger-than-average newborn (such as an infant of a diabetic mother)
• Making sure the person gets enough calories, to prevent low blood sugar and promote growth
• Small size

Order trimox 250 mg without prescription

If you feel antibiotics for uti prescription trusted 250 mg trimox, however antibiotic resistance gene transfer 500 mg trimox order with mastercard, risk depends on: that a vertical incision is necessary due to size and N number infection vaginal itching generic 500 mg trimox, site and size of fibroids number of fibroids you should consider again N surgical technique whether you have the skills to do the operation as N perioperative infection these myomectomies need advanced experience N intraoperative opening of the uterine cavity and skills. N the capability of healing of the patient’s tissue Fibroids easily accessible to abdominal myo- N time elapsed since operation. Submucosal fibroids should have a significant intra- 20. These figures, however, are for mural part, as otherwise they can’t be located laparoscopic surgery, a method which will be abdominally during the operation. Furthermore, all patients in miscarriage (see Chapter 14). It is very important to consider that for patients All other patients becoming pregnant after myo- with infertility, recurrent miscarriage and desire for mectomy have to deliver in hospital, with theatre future pregnancies, a lot is at risk when undertaking facilities available 24 h, under any circumstances. If a the operation, since you are never sure if you can woman is not ready for this prior to surgery, myo- avoid a hysterectomy beforehand. Please be aware of the fact that the biggest cause of subfertility in low-resource Adverse events settings is tubal blockage and you should rule this Although the uterus is preserved, myomectomy is a out before surgery in patients who come with major abdominal operation and has as such adverse fibroids and a history of infertility (see Chapter 16). It is always wise to examine the patient yourself as The intraoperative placement of tourniquets is a surgeon, before the operation and again while she an effective method but you have to be sure of the is already anesthetized. This method should only be chosen and position of the fibroids and the uterine mobi- where misoprostol or bupivacaine/epinephrine are lity you will have to decide whether you can use a 14 not available. The technique for applying tourni- transverse or vertical incision of the abdominal wall quets for reduction of hemorrhage in myomec- for your operation. Here it is important to consider tomy is as follows: the aim of the operation: most patients for myo- mectomy undergo the operation in order to be- • Incise the anterior part of the peritoneum come pregnant and deliver safely. Thus, you will between the bladder and the uterus and reflect need the best access to the fibroids and the uterus to the bladder inferiorly. Therefore it is some- side of the uterine isthmus cranial to the uterine times wise to consider a vertical incision especially arteries. If you are • Pass a 20-cm length part of sterile infusion set more experienced you can choose a horizontal in- through the holes and tie it tightly anteriorly cision like a Pfannenstiel or Joel Cohen incision. If around the cervix at the level of the internal there are few or a single smaller fibroid which is cervical os. A mini-lap is cheaper and needs a shorter hos- a small forceps to occlude the ovarian vessels. The final approach to the fibroids is not dependent The most important complication in myo- on the choice of skin incision or method for mectomy is hemorrhage with consequent anemia. Here is a stepwise approach: Intraoperatively this may impair your access to the former fibroid capsule and hamper uterine recon- • Increase access to the uterus by either packing struction resulting in a weak scar. Thus, you must the bowel with damp drapes or by putting the take measures to reduce bleeding. A Cochrane me- patient in slight Trendelenburg position. Although the • Inspect the uterus for size and site of the fibroids sample sizes of these studies were small, the in order to determine where to best place your Cochrane collaboration’s conclusion was that miso- uterine incision: prostol, bupivacaine with epinephrine, tranexamic N Incise where you will be able to ‘harvest’ the acid or a triple tourniquet have led to a significant most fibroids with one incision. N Posterior incisions might lead to intestinal Misoprostol is readily available in most resource- adhesions. Give 400 µg vaginally 1h before the N Aim for a low anterior midline incision. In settings where spinal anesthesia know that for cesarean section scars a low in- is performed, bupivacaine 0. Inject 50 ml of bupivacaine ture15 but there is no stronger evidence for together with 0. If it is visible you can tie it with a 2–0 Vicryl or catgut suture. Figure 4 Fibroid dissection from its bed Abdominal hysterectomy • If your incision is a low anterior incision, incise Definition the bladder peritoneum and reflect the bladder A hysterectomy is the removal of the uterus with or downwards. For uterine fib- • Incise the uterine serosa and myometrium at the roids this is usually done via an abdominal incision top of the protruding fibroid until you see its either transverse as the above mentioned Pfannen- particular whitish tissue. If an older lady has been fibroid to identify it and make sure you have postmenopausal for some years (i.

Trusted trimox 250 mg

Prevalence and factors associated with renal dysfunction among HIV-infected patients antimicrobial jackets buy trimox 500 mg on line. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy Kidney International 2001;80:302-9 infection quest wow trimox 500 mg order overnight delivery. HAART-related nephropathies in HIV – infected patients bacteria 1 negative hpf generic trimox 500 mg with mastercard. Day SL, Leake Date HA, Bannister A, Hankins M, Fisher M. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. Proximal tubular renal dysfunction or damage in HIV-infected patients. Nephrotoxicity of Antiretroviral Agents: Is the List getting longer? Prevalence of adverse events associated with potent antiretroviral treat- ment: Swiss HIV Cohort Study. AIDS Research and Treatment, Volume 2011, Article ID 354908 Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. Franceschini N, Napravnik S, Eron JJ Jr, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Fanconi syndrome and acute renal failure in a patient treated with Tenofovir: a call for caution. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside transcriptase inhibitor- based therapy. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease. HIV-associated immune complex glomerulonephritis with “lupus-like” features: a clin- icopathologic study of 14 cases. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral- naive HIV-1-infected patients data from a double-blind randomized active-controlled multicentre study. Renal safety of tenofovir in HIV treatment-experienced patients. Renal tubular transporters and antiviral drugs: an update. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral- naive HIV-1-infected patients data from a double-blind randomized active-controlled multicentre study. Progression of renal impairment under therapy with tenofovir. MYH9 is associated with nondiabetic end-stage-renal disease in African Americans. Net Genet 2008; 40:1185-1192 Kidney disease: Improving global outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglob- ulin, percentage of tubular reabsorption of phosphate and alcaline phosphatase levels. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Pharmacokinetics of enfurvitide in a patient with impaired renal function; Clin Infect Dis 2004; 39: e119-e121 Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604- 612 Lucas, GM, Metha SH, Atta MG, et al.

Trimox 500 mg order on-line

No serious AEs considered by the investigator to be 502 patients randomized rosuva 10mg: 49% (p<0 antibiotic resistance uganda cheap trimox 500 mg online. Trigs reduction from baseline at 12 weeks: 4) antibiotics for treatment of sinus infection generic trimox 250 mg buy online, abdominal pain (2 vs infection ios purchase trimox australia. No parva: 13% clinically significant ALT or CK elevations. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Funding Source Paoletti et al. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Inclusion Criteria/ Patient Clinical Trial Population Exclusion criteria Intervention Rawlings, 2009 Men with stale atherosclerosis and Unstable angina or revascularization within 3 months of study Atorvastatin 40 mg vs rosuvastatin 10 mg Multicenter (2 cardiology fasting LDL-C levels >=100 mg/dL enrollment, malignancy, chronic inflammatory disease, acute for 4 weeks clinics), double-blind off statin therapy. Presence of infection, history of myositis/myopathy, liver transaminases >2 times atherosclerosis determined by ULN, creatine phosphokinase greater than the ULN, and reluctance to >=50% stenosis in at least one discontinue statin therapy. Mean baseline LDL-C: 141 (SD 6) mg/dl N=30 Schneck et al, 2003 Men and women age 18 and older Pregnant or lactating women or women of childbearing potential not Atorva 10, 20, 40, or 80 mg qd or R, DB, MC with hypercholesterolemia and using a reliable form of contraception, as well as patients with a rosuvastatin 5, 10, 20, 40, or 80 mg qd for without active arterial disease history of heterozygous 6 weeks. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Results (mean changes in lipoprotein levels) Harms/Comments Rawlings, 2009 Percent change from baseline, atorvastatin vs rosuvastatin: Not reported Multicenter (2 cardiology LDL-C: -45. Withdrawals due to adverse events infrequent (1 patient each in 374 patients randomized 61. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Funding Source Rawlings, 2009 NIH and Foundations Multicenter (2 cardiology clinics), double-blind Schneck et al, 2003 Supported by R, DB, MC AstraZeneca Pharmaceuticals 374 patients randomized (n=165 aorta, 209 rosuva) 6 weeks Statins Page 164 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 1. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Inclusion Criteria/ Patient Clinical Trial Population Exclusion criteria Intervention Schuster et al. Patients aged >=18 years, with Pregnant and lactating women, women not using reliable 6 week dietary lead-in phase, then 2004 CHD or other atherosclerotic contraception, patients with a history of homozygous familial randomization to 5 arm trial system R,OL,MC,ITT disease, type 2 diabetes, a CHD hypercholesterolemia or known type III hyperlipoproteinemia, with (drug a for 8 weeks then drug b or c for risk >20% over 10 years, with LDL- active arterial disease (e. Statins Page 165 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 1. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Results (mean changes in lipoprotein levels) Harms/Comments Schuster et al. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Funding Source Schuster et al. Sponsored by Astra 2004 Zeneca R,OL,MC,ITT 5-arm trial that included statin switching (to rosuvastatin) at 8 weeks 3140 patients randomized 16 weeks of treatment Statins Page 167 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 1. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Inclusion Criteria/ Patient Clinical Trial Population Exclusion criteria Intervention Schwartz et al, 2004 Patients aged >18 years, with LDL- Pregnant women, patients currently taking concomitant drugs known After a 6 week dietary lead-in, treatment C levels >=160 and< 250 mg/dL, to affect the lipid profile or to present a potential safety concern, a for the first 12 weeks: R, DB, MC and trig levels <=400 mg/dL, and history of active arterial disease (e. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Results (mean changes in lipoprotein levels) Harms/Comments Schwartz et al, 2004 Efficacy analysis for 382 patients: "Although adverse events were frequently reported in these high-risk patients, % LDL-C change from baseline they were generally mild and not attributed to trial medication. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Funding Source Schwartz et al, 2004 Sponsored by Astra Zeneca R, DB, MC 382 patients randomized 24 week treatment period Statins Page 170 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 1. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Inclusion Criteria/ Patient Clinical Trial Population Exclusion criteria Intervention Stalenhoef et al. Also >3X ULN; and use of prohibited concomitant medications. Statins Page 171 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 1. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Results (mean changes in lipoprotein levels) Harms/Comments Stalenhoef et al. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Funding Source Stalenhoef et al. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Inclusion Criteria/ Patient Clinical Trial Population Exclusion criteria Intervention Strandberg et al, 2004 Men and women >=18 years with A history of serious adverse events or hypersensitivity to an hMG-CoA rosuv 10 mg/d LDL-c level >135 mg/dL for statin- reductase inhibitor other than the study drugs; active hepatic disease; atorv 10 mg PO OD R (2:1), OL, MC, 2-arm naïve patients or >120 mg/dL in homozygous or heterozygous familial hypercholesterolemia (FH); study, ITT patients using the starting dose of unstable angina; elevated serum creatinine concentration (>220 optional extension period for rosuv pts who another lipid-lowering drug. Statins Page 174 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 1. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Results (mean changes in lipoprotein levels) Harms/Comments Strandberg et al, 2004 Efficacy analysis for 911 patients (rosuv 10mg/d, n= 627; atorv 10mg/d, n= Patients experiencing any AE (estimated from graph): 284) Rosuv ~38% (n=261) R (2:1), OL, MC, 2-arm Atorv ~37% (n=125). Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Clinical Trial Funding Source Strandberg et al, 2004 Supported by a grant from AstraZeneca R (2:1), OL, MC, 2-arm study, ITT 1024 patients randomized (n=686 to rosuv 10 mg/d, n=338 to atorv 10 mg/d) 12 weeks Statins Page 176 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 1. Trials comparing LDL-c lowering/HDL-c raising abilities of 2 or more statins Inclusion Criteria/ Patient Clinical Trial Population Exclusion criteria Intervention Wolffenbuttel et al. Men and women with type 2 use of lipid-lowering drugs after visit 1, or a history of serious or After a 6-week dietary lead-in, treatment 2005 diabetes who had received hypersensitivity reactions to statins. Concomitant treatment with erythromycin, clarithromycin, azole antifungal agents, cyclosporin, antiviral agents, phenytoin, carbamazepine, phenobarbital, or nefazodone. Statins Page 177 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 1.

250 mg trimox order with amex

Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: Part III: Age differences antibiotic ointment for babies discount 250 mg trimox visa. Neumann T antibiotic resistance epidemiology buy generic trimox 500 mg online, Lulsdorf KA infection 4 the day after buy cheap trimox, Krings P, Reinsch N, Erbel R. Coronary artery disease in HIV-infected subjects : Results of 101 coronary angiographies. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 2005; 112:3602-3607 598 Interdisciplinary Medicine Nosanchuk JD. Usefullness of 24-hour ambulatory blood pressure monitoring in people living with HIV. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. Acute idiopathic hemorrhagic pericarditis with cardiac tamponade as the initial pres- entation of acquired immune defi-ciency syndrome. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33:1635-1701 Pruznak AM, Hong-Brown L, Lantry R, et al. Skeletal and cardiac myopathy in HIV-1 transgenic rats. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. Myocardial fas ligand expression increases susceptibility to AZT-induced cardiomyopathy. Prevalence and Risk Factors Associated with Pulmonary Hypertension in HIV-Infected Patients on Regular Follow-Up. Reversible right ventricular dysfunction in patients with HIV infection. South Med J 2006;99:274-8 Rathbun CR, Liedtke MD, Blevins SM, et al. Electrocardiogram abnormalities with atazanavir and lopinavir/riton- avir. Effect of gender and highly active antiretroviral therapy on HIV-related pul- monary arterial hypertension: results of the HIV-HEART Study. Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. Cardiovascular risk factors in HIV: results of the HIV-HEART study. Echocardiographic Findings and Abnormalities in HIV-Infected Patients: Results from a Large, Prospective, Multicenter HIV-Heart Study. American Journal of Cardiovascular Disease 2011, 1: 176–184. Ren X, Trilesskaya M, Kwan DM, Nguyen K, Shaw RE, Hui PY. Comparison of outcomes using bare metal versus drug-eluting stents in coronary artery disease patients with and without human immunodeficiency virus infec- tion. Epidemiology of pericardial effusions at a large academic hospital in South Africa. Immune reconstitution inflammatory syndrome and human immunodefi- ciency virus-associated myocarditis. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol).

Discount 500 mg trimox overnight delivery

A pooled 36 analysis of three placebo-controlled trials reported that reductions in A1c were not related to age and that hypoglycemia was not more frequent in subjects ≥ 65 years of age antibiotic resistance history purchase 500 mg trimox with mastercard. No primary study examined the efficacy or effectiveness of exenatide in subgroups defined by age or other characteristics antibiotics for resistant uti buy 500 mg trimox amex. Diabetes Page 49 of 99 Final Report Drug Effectiveness Review Project Applicability of efficacy virus list buy trimox 250 mg lowest price, effectiveness, and safety data to general diabetes populations The studies identified for this review are rather homogeneous, relatively small, and may be rather selected, thus applicability to broader diabetes populations may be limited. Study subjects were homogeneous across studies for age, sex, and baseline A1c in both the In the placebo- and active-controlled trials. Significant comorbidities were excluded in the three placebo-controlled 31-33 studies reporting that characteristic and comorbidities were not mentioned in three of the four 26, 28, 30 active-controlled trials. Most studies reported only the number of subjects randomized, and randomization occurred in all placebo-controlled trials after a run-in of injected placebo. In other words, the number of potential study subjects who did not tolerate twice daily injections and who were therefore not included in the study was usually not reported. Open label extension studies were of highly selected populations who completed the primary study and who volunteered to continue (or start if on placebo) exenatide. Diabetes Page 50 of 99 Final Report Drug Effectiveness Review Project Table 13. Characteristics of exenatide observational studies in adults with type 2 diabetes a Age (years) (SD) a % Male a Baseline Sample % White a a Author, size (N) % Hispanic A1c (%) a Year Follow-up Diabetes duration Weight (kg) Combination Primary trial a 2 a Country (weeks) (years) BMI (kg/m ) Intervention therapy citations 55(10) Blonde, Buse, 2004 974 61 8. Abbreviations: BID, twice daily; ITT, intention-to-treat population; MET, metformin; SU: sulfonylurea; TZD, thiazolidinedione. Diabetes Page 51 of 99 Final Report Drug Effectiveness Review Project Table 14. Exenatide summary evidence table Type 2 Diabetes Quality of evidence Conclusion No study examined children or adolescents Key Question 1. A1c improved more with exenatide than with placebo, both added to various oral agents: between-group difference Placebo-controlled trials, both (exenatide minus placebo): 5 mcg BID: - groups receiving oral diabetes 0. No study examined health or quality-of-life outcomes. Health outcomes: No data Exenatide was not compared with other active drugs except insulin. A1c improved in both treatment groups with no significant differences between Active-controlled trials, both treatments. The substitution of exenatide groups receiving oral diabetes for insulin did not improve A1c in either agents group. Glycemic control: Fair quality, 3 Efficacy and effectiveness for RCTs achieving glycemic control when Exenatide produced significant weight loss added to other hypoglycemic compared to weight gain with insulin Weight change: Fair quality, 3 agents compared to conventional (difference 4-5. Quality of life was examined in only one study, with no significant differences Health outcomes: Poor quality, 1 between exenatide and insulin glargine RCT despite higher rates of gastrointestinal adverse effects with exenatide. Total withdrawal rates were higher with exenatide than with insulin treatment or placebo. Harms for achieving glycemic control when compared to other Nausea: Good quality, 7 RCTs Withdrawal rates due to adverse events hypoglycemic agents as were higher with exenatide 10 mcg BID monotherapy or combined Hypoglycemia: Good quality, 7 than with placebo; there was no difference therapy? Harms for achieving glycemic Severe, long-term, or idiosyncratic Nausea and vomiting were the most control when added to other adverse events: Fair, most data frequent adverse events and rates were hypoglycemic agents compared from less than 30-week follow-up. Nausea persisted in 8% of subjects after 2 years (1 study). Diabetes Page 52 of 99 Final Report Drug Effectiveness Review Project Type 2 Diabetes Quality of evidence Conclusion The incidence of hypoglycemia was elevated with exenatide 5 and 10 mcg BID compared with placebo (both groups received oral agents), but was significant only for the higher dosage. Hypoglycemia rates were similar between insulin-treated and exenatide groups. There was no evidence of cardiovascular, pulmonary, hepatic, or renal adverse effects across studies, and rates of serious events were similar between treatment groups. Are there One study showed exenatide improved A1c subgroups of patients for which to a similar degree in persons over and Poor quality, 1 subgroup analysis exenatide is more or less suitable under 65 years of age. Abbreviations: BID, twice daily; RCT, randomized controlled trial. Diabetes Page 53 of 99 Final Report Drug Effectiveness Review Project Sitagliptin We identified 166 citations by various methods of literature searching (Figure 5). Eleven randomized controlled trials and 2 systematic reviews fulfilled inclusion criteria. No comparative cohort or case-control studies were identified reporting either long-term benefits or adverse events.

Surus, 35 years: Adequate (that is, unbiased) methods of randomization include computer generated schedules and random-numbers tables. Prognosis and clinical evaluation of infection caused by Rhodococcus equi in HIV-infected patients: a multicenter study of 67 cases.

Flint, 34 years: Continuous epidemiological surveillance of local bacteremias is necessary, along with stringent enforcement of antibiotic stewardship programs in cancer patients. Were potential confounding variables and risk factors identified and examined using acceptable statistical techniques?

Ilja, 30 years: Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive- compulsive disorder. Oxybutynin immediate-release was found to have a greater rate of dry mouth compared with oxybutynin extended-release, oxybutynin transdermal, and tolterodine extended-release and immediate-release in the meta-analysis.

Ines, 32 years: Although these studies were relatively small, no adverse outcomes 4. The study is now being conducted and is of 84% and 68%, respectively, at 5 years median follow-up Tumor available to all AMC, Southwest Oncology Group (SWOG), histogenesis was the only characteristic associated with lymphoma- specific outcome.

Marlo, 29 years: It is possible to increase the majority of patients by improving our understanding of how to probability of finding a donor by taking haploidentical related overcome the limitations of alternative donor transplantation, donors into consideration, because the majority of patients have a including delayed engraftment and poor immune cell reconstitution. Venlafaxine in the treatment of premenstrual dysphoric disorder.

Lares, 50 years: Three-month mortality rate and clinical thromboembolism with the angiogenesis inhibitor bevacizumab predictors in patients with venous thromboembolism and in cancer patients: a meta-analysis. N C I:N ationalC ancerInstitute;U L N :U pperlimitofnormal Antiemetics Page 189 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 3.

Armon, 28 years: The PPV of PET-2 in HL needs to be Noninferiority study analyses further improved to better guide management even after implemen- There are several salient considerations when examining results from a tation of the Deauville 5PS criteria. Comparison of the acceptability of the Ventolin metered-dose inhaler and the Bricanyl Turbuhaler.

Kaelin, 43 years: However, another study showed that some patients without previous treatment with attachment inhibitors developed resistance to temsavir due to subtype-related polymorphisms in the gp120 region (Charpentier 2012). Symbol use: Drug X > Drug Y = statistically significant difference in outcomes favoring Drug X; Drug X > Drug Y trend = point estimate favors Drug X, but the difference is not statistically significant or tests of statistical significance were NR; No difference = no statistically significant difference or tests of statistical significance were not reported and outcomes are similar.

Sulfock, 58 years: In the 20-week study comparing exenatide to rosiglitazone with all participants on background metformin therapy, there was no significant difference in improvement in HbA1c between the exenatide and rosiglitazone arms (change with exenatide -0. Antiemetic control in cancer patients treated with highly emetogenic chemotherapy.

Fabio, 39 years: One meta-analysis reported results 68 from ten trials (n=270, seven trials versus baclofen and three versus diazepam) and the other reported results of these plus one additional trial of tizanidine versus baclofen (n=288). Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Sivert, 46 years: Confidence intervals around the estimate of effect are one way of expressing precision, with a narrower confidence interval meaning more precision. High-dose chemotherapy (DT-PACE, DCEP) frontline setting, many patients at relapse have not been treated with In end-stage, multidrug resistant myeloma, very few options exist melphalan.

Ingvar, 64 years: Studies evaluating the utility of levofloxacin prophylaxis during ALL induction and in those being treated with intensive therapy for relapsed disease are being done through the Dana-Farber Cancer Institute consortium and COG, respectively. Based on the effects of NOACs on the terminal steps of clot formation, it appears that they would prolong both the PT and aPTT and that these assays could perhaps be used to assay NOAC levels.

Copper, 55 years: Fresh whole blood use Characterizing polymorphisms and allelic diversity of von by forward surgical teams in Afghanistan is associated with Willebrand factor gene in the 1000 Genomes. Natalizumab and mitoxantrone were more effective than placebo for relapse-related and disease progression outcomes in placebo-controlled trials.

Daro, 56 years: Studies included in the meta-analyses used similar efficacy outcome measures. Absence of food interactions, limited hepatic metabolism, and few Limited availability of assays for measuring drug levels and absence strong drug interactions.

Ernesto, 53 years: It has been randomized crossover trial that compared unfractionated heparin hypothesized that low-dose aspirin might have a positive effect on 5000 units subcutaneously twice daily and aspirin from the day of the success of assisted reproduction by increasing uterine and embryo transfer with negative pregnancy test or week 14 of ovarian blood flow, thereby enhancing implantation and ovarian pregnancy with placebo in women with recurrent implantation response to stimulation. If details of electronic database searches and other identification strategies are given, the answer to this question usually is yes.

Ressel, 60 years: Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. The results of the drug and placebo groups are then compared to see if the drug is more effective in treating the condition than the placebo is.

References

• Wong B, Perfect JR, Beggs S, Wright KA. Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immun 1990;58(6):1664-70.
• Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35:1-23.
• Sollinger HW, Ploeg RJ, Eckhoff DE, et al. Two hundred consecutive simultaneous pancreas-kidney transplants with bladder drainage. Surgery. 1993;114:736-743.
• Hansen K, Legech A-M. The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990.
• Clayman RV, Garske GL, Lange PH: Total nephroureterectomy with ureteral intussusception and transurethral ureteral detachment and pull-through, Urology 21:482n486, 1983.
• Yennurajalingam S, Reddy A, Tannir NM, et al. High-dose Asian ginseng (Panax ginseng) for cancer-related fatigue: a preliminary report. Integr Cancer Ther 2015;14(5):419-427.
• Trompeter M, Brazda T, Remy CT, et al. Non-occlusive mesenteric ischemia: etiology, diagnosis, and interventional therapy. Eur Radio/. 2002; 12: 1179-1187.
• Lerche W: The esophagus and pharynx in action: A study of structure in relation to function, Springfield, IL, 1950, Charles C Thomas. 26.